1. Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: a prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach
- Author
-
Simone Sala, Vincenzo Santinelli, Francesco Manguso, Ornella Santinelli, Gabriele Vicedomini, Filippo Gugliotta, Amedeo Ferro, Carlo Pappone, Simone Gulletta, Eustachio Agricola, Gabriele Paglino, Giuseppe Augello, Alberto Zangrillo, Ottavio Alfieri, Nicoleta Sora, Pappone, C, Manguso, F, Vicedomini, G, Gugliotta, F, Santinelli, O, Ferro, A, Gulletta, S, Sala, S, Sora, N, Paglino, G, Augello, G, Agricola, E, Zangrillo, Alberto, Alfieri, Ottavio, and Santinelli, V.
- Subjects
Tachycardia ,Male ,Tachycardia, Ectopic Atrial ,medicine.medical_specialty ,medicine.medical_treatment ,Ablation of atrial fibrillation ,Iatrogenic Disease ,Catheter ablation ,Disease-Free Survival ,Physiology (medical) ,Internal medicine ,Atrial Fibrillation ,Medicine ,Humans ,Life Tables ,Single-Blind Method ,Prospective Studies ,Prospective cohort study ,Atrial tachycardia ,Aged ,business.industry ,Atrial fibrillation ,Middle Aged ,medicine.disease ,Ablation ,Surgery ,Treatment Outcome ,Pulmonary Veins ,Cardiology ,Catheter Ablation ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Complication ,Follow-Up Studies - Abstract
Background— Circumferential pulmonary vein ablation (CPVA) is effective in curing atrial fibrillation (AF), but new-onset left atrial tachycardia (AT) is a potential complication. We evaluated whether a modified CPVA approach including additional ablation lines on posterior wall and the mitral isthmus would reduce the incidence of AT after PV ablation. Methods and Results— A total of 560 patients (291 men, 52%; age, 56.5±7.3 years) entered the study; 280 were randomized to CPVA alone (group 1) and 280 to modified CPVA (group 2). The primary end point was freedom from AT after the procedure. In group 1, 28 patients (10%) experienced new-onset AT, and 41 (14.3%) experienced recurrent AF. In group 2, 11 patients (3.9%) experienced AT, and 36 (12.9%) had recurrent AF. Group 1 was more likely to experience AT than group 2 ( P =0.005). Freedom from AF after ablation was similar in both groups ( P =0.57). Among those in group 1, gap-related macroreentrant AT was documented in 23 of the 28 patients (82%), and focal AT was found in 5 (18%). In group 2, gap-related macroreentrant AT was found in 8 of the 11 patients (73%), and focal AT was seen in 3 (27%). Two patients in group 1 and 1 patient in group 2 had both AT and AF. The strongest predictor of AT was the presence of gaps ( P Conclusions— Modified CPVA is as effective as CPVA in preventing AF but is associated with a lower risk of developing incessant AT.
- Published
- 2004